Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial

PURPOSE: To determine whether SD-101, a Toll-like receptor 9 agonist, potentiates the antitumor activity of anti-PD-1 antibodies in patients with anti-PD-1/PD-L1 naïve, recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). PATIENTS AND METHODS: Patients with PD-1 Ab-naïve HNSCC receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Ezra E.W., Nabell, Lisle, Wong, Deborah J., Day, Terry, Daniels, Gregory A., Milhem, Mohammed, Deva, Sanjeev, Jameson, Michael, Guntinas-Lichius, Orlando, Almubarak, Mohammed, Strother, Matthew, Whitman, Eric, Chisamore, Michael, Obiozor, Cynthia, Bagulho, Teresa, Gomez-Romo, Jose, Guiducci, Cristiana, Janssen, Robert, Gamelin, Erick, Algazi, Alain P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365346/
https://www.ncbi.nlm.nih.gov/pubmed/34965944
http://dx.doi.org/10.1158/1078-0432.CCR-21-1411

Ejemplares similares

Ejemplares similares